

Global event on enhancing the sustainability of investment for vaccine manufacturing in Africa.
27-29 June 2023

United Nations Conference Centre, UNECA, Addis Ababa, Ethiopia

Presentation of opportunities for investment and partnerships on vaccines and biopharmaceuticals.

A. Who we are, & what we do

- Pasteur Institute of Algeria (PIA) is an Algerian **public institution of industrial and commercial character**. It was established in 1894 with an initial mission to provide rabies treatment for bitten individuals. Over time, it evolved into a centre for scientific research on infectious diseases.
- Currently, the institute has 3 missions:
 - It is a **research and diagnostics** reference institute in the **biological field and infectious diseases**;
 - The **production and distribution of serums and vaccines** for human and veterinary use;
 - **Scientific training**.
- The company has **7 sites across the country**, 4 of which are located in Algiers. PIA is part of the **Pasteur Institutes Network**.



El Hamma site



Dely Brahim site



Kouba site

- Apart from its commercial diagnostics services, PIA current product portfolio includes:

1. Vaccines



RAGIVAC (for human use)

- Tissue-based inactivated **rabies vaccine** (LP Saigon strain); antigenic titer ≥ 0.3
- **Form:** Each vial of freeze-dried vaccine is reconstituted with 2 ml of solvent



CLAVAX (for veterinary use)

- Culture-based attenuated **sheep pox vaccine** (strain RM65); TCID₅₀ ≥ 1000
- **Form:** Each vial of freeze-dried vaccine is reconstituted with 3 ml of solvent; each vial contains 100 vaccinating doses.



VET-ERA (for veterinary use)

- Culture-based alive **rabies vaccine** (ERA strain).
- **Form:** Each vial of freeze-dried vaccine is reconstituted with 2 ml of solvent

2. Therapeutic sera



IPASCORP

- Anti-scorpion venom serum – F(ab')₂ fragments of equine antivenom immunoglobulins monospecific against *Androctonus australis hector*.
- Form: 5 ml vials neutralizing at least 15 LD₅₀/ml/20 g of mouse.



IPAVIP

- Anti- viper venom serum – F(ab')₂ fragments of equine antivenom immunoglobulins bispecific against *Cerastes cerastes* and *Macrovipera lebetina*.
- Form: 5 ml vials neutralizing at least 40 DL₅₀/ml/20 g of mouse and 20 DL₅₀/ml/20 g of mouse for *C. cerastes* et *M. lebetina*, respectively.



IPARAB

- Antirabies serum – F(ab')₂ fragments of equine antirabies immunoglobulin.
- Form: 5 ml vials containing at least 1000 IU of F(ab')₂ fragments.

3. Culture media and diagnostics reagents

More than 300 products (complete list available upon request).

4. Laboratory animals

Mice, rats and rabbits.

■ Biopharmaceuticals annual manufacturing:

	Product	Form	2022 campaign
Vaccines	Antirabies vaccine for human use (RAGIVAC®)	Freeze-dried – 2 ml vials	365 556
	Sheep pox vaccine (CLAVAX®)	Freeze-dried – 100 doses per vial	23 000 000 doses
Therapeutic sera	Scorpion antivenom (IPASCORP®)	5 ml vials	80 072
	Vipers antivenom (IPAVIP®)	5 ml vials	10 749
	Total production	5 ml vials	90 821

▪ **Development goals related to biopharmaceuticals manufacturing**

- Building a new GMP-certified facility for the manufacturing of vaccines and therapeutic sera.
- Training the workforce to recent biopharmaceutical manufacturing technologies and cGMPs standards.
- Expanding the human vaccines portfolio of PIA to eventually cover the national needs.
- Expanding the veterinary vaccines portfolio of PIA.
- Improve the preparedness to future health and economic challenges.
- Export of vaccines.
- Improve R&D capabilities on vaccines particularly with mRNA-based and vector-based vaccines.

B. What are we offering

- Exclusive access to the national vaccines market of **more than \$ 110 million value**.
- **Land, financial contribution, human resources** to be allocated for the biopharmaceuticals manufacturing project.
- **Strategic geographical location** for international trade, at the center of the Mediterranean region, connecting Africa, Europe and the Middle East.

C. What are we looking for

- **Investing partner(s) or investor(s)** to contribute to the funding of the construction of the new manufacturing facility of vaccines and/or therapeutic serums.
- A **manufacturing partnership** with a producer of **WHO prequalified vaccines**.

Contact:

▪ **Pr Derrar Fawzi – Managing Director**

Email : directiongenerale@pasteur.dz ; fderrar@pasteur.dz ; fawziderrar@gmail.com

Phone : +21323367504

Fax : + 21323367549

▪ **Dr Issad Mourad – Production Director**

Email : missad@pasteur.dz ; m_issad@yahoo.fr

Phone / Fax : +21323786477

▪ **Dr Benazzouz M. Safouane – Head of the Therapeutic serums production laboratory**

Email : msbenazzouz@pasteur.dz ; safouanebenazzouz@gmail.com

Phone / Fax : +21323786477

Website:

<https://pasteur.dz/>